OSK-1;
OSK-1 是有效的 Kv 通道阻断剂,对 Kv1.1、Kv1.2、Kv1.3 的 IC50 分别为 0.6 nM、5.4 nM、0.014 nM。OSK1 是 Ca2+ 激活的 KCa3.1 通道的中度阻滞剂,IC50 为 225 nM。OSK-1 属于 α-KTx3 毒素,有潜力用作免疫抑制药物。
OSK-1 Chemical Structure
CAS No. : 183815-75-0
规格 | 是否有货 | ||
---|---|---|---|
100 mg | ; | 询价 | ; |
250 mg | ; | 询价 | ; |
500 mg | ; | 询价 | ; |
* Please select Quantity before adding items.
生物活性 |
OSK-1 is a potent Kv channel blocker with IC50s of of 0.6 nM, 5.4 nM, 0.014 nM for Kv1.1, Kv1.2 and Kv1.3, respectively. OSK1 is a moderate blocker of Ca2+-activated KCa3.1 channel with an IC50 of 225 nM. OSK-1 belongs to α-KTx3 toxins and is used as a immunosuppressive drug[1]. |
IC50 Target |
IC50: 0.6 nM (Kv1.1), 5.4 nM (Kv1.2), 0.014 nM (Kv1.3) and 225 nM (KCa3.1)[1] |
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
OSK1 has no effect on KCa2.1, KCa2.2, KCa2.3 and KCa1.1 channels when in the micromolar concentration range, whereas it shows a moderate activity on KCa3.1 channel (also referred to as IK1 or SK4) with an IC50 value of 225 nM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||
体内研究 (In Vivo) |
OSK1 is lethal in mice by intracerebroventricular injection, with a LD50 (50% lethal dose) value of 2 μg/kg[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||
分子量 |
4205.17 |
||||||||||||||||||||
Formula |
C28H40N4O6 |
||||||||||||||||||||
CAS 号 |
183815-75-0 |
||||||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||||||||||||||||||||
Solvent Solubility |
In Vitro:;
H2O Peptide Solubility and Storage Guidelines: 1.;;Calculate the length of the peptide. 2.;;Calculate the overall charge of the entire peptide according to the following table:
3.;;Recommended solution:
|
||||||||||||||||||||
参考文献 |
|